This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Genetics, Other  • Statistics and Research Methods  • Review  • Randomized Controlled Trial  • Neurogenetics  • Neurology, Other  • Alert me on articles by topic

Challenges and Opportunities

Alan I. Faden, MD; Bogdan Stoica, MD

Arch Neurol. 2007;64(6):794-800.

The ability of pharmacological agents to limit secondary biochemical damage and cell death has been well established in numerous animal models of stroke, head injury, and spinal cord injury, yet the results of such neuroprotective treatment strategies in human injury have been disappointing. A number of conceptual and methodological issues have undoubtedly contributed to the difficulties in translating the experimental results to the clinic. Most recently, different experimental approaches and altered clinical trial methodologies have provided renewed, albeit cautious, optimism regarding future clinical trials of neuroprotective agents. Herein, we reviewed both the critical problems and potential solutions, emphasizing recent experimental and clinical work.

Author Affiliations: Department of Neuroscience, Georgetown University Medical Center, Washington, DC.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Tale about Tau
Ashe
NEJM 2007;357:933-935.
FULL TEXT